Wall Street veteran and Manhattanville College School of Business finance professor Gary Jacobi analyzes the 2016 performance of the largest publicly traded companies based in Westchester and offers his forecast of what to expect from them this year.
 |
(IBM), Armonk
2016 Snapshot: With the best year of any publicly traded large Westchester company, IBM stock was up 21.19%; when coupled with their 3.36% dividend, shareholders were up nearly 25% in 2016.
Average 2016 Stock Price: $143.43
2017 Outlook: Coming off a strong 2016, IBM should have a strong 2017 if it can stay ahead of the pace of change that characterizes the tech sector.
 |
(ITT), White Plains
2016 Snapshot: The second-best performing stock of the group, ITT was up 19.19% since it went public in May 2016, offering a 3.36% dividend.
Average 2016 Stock Price: $36.11
2017 Outlook: With a Market Cap of $3.61bn, ITT has plenty of room to grow and is well positioned to have an excellent 2017.
 |
(MA), White Plains
2016 Snapshot: Providing solid total returns, MasterCard was up 6.23% and paid a quarterly dividend of $0.19, for a dividend yield of 0.84%.
Average 2016 Stock Price: $93.73
2017 Outlook: MA has a Market Cap of $112.7bn and is well situated to grow with the rapidly changing payment/transaction industry.
 |
(PEP), Purchase
2016 Snapshot: PepsiCo shareholders were up 8.79% for the year, with a 5.95% gain in the stock price and an additional 2.8% dividend.
Average 2016 Stock Price: $101.89
2017 Outlook: As consumers move away from sugary drinks, and in a highly competitive arena, Pepsi could have a tough road ahead in 2017. With that said, PEP should be able to match its 2016 appreciation of 5.95%.
 |
(REGN), Tarrytown
2016 Snapshot: The worst performer of the group was Regeneron, which saw its stock fall by 30% in 2016. Approximately two-thirds of this decline was attributable to an industry-wide slide of biotech stocks as a whole.
Average 2016 Stock Price: $439.55
2017 Outlook: After a tough 2016, it’s hard to be optimistic about the early part of 2017. But, Regeneron has an active pipeline, and just one breakthrough drug could turn 2017 into an excellent year for REGN and its shareholders.
